CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE SODIUM SUCCINATE
✉ Email this page to a colleague
All Clinical Trials for METHYLPREDNISOLONE SODIUM SUCCINATE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000579 ↗ | Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1994-09-01 | The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented. |
NCT00097448 ↗ | Sudden Deafness Treatment Trial | Completed | National Institute on Deafness and Other Communication Disorders (NIDCD) | Phase 3 | 2004-12-01 | This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours). |
NCT00097448 ↗ | Sudden Deafness Treatment Trial | Completed | Massachusetts Eye and Ear Infirmary | Phase 3 | 2004-12-01 | This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours). |
NCT00185692 ↗ | Allogeneic Transplantation From Related Haploidentical Donors | Completed | Stanford University | Phase 2 | 2000-08-01 | The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG). |
NCT00290602 ↗ | Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome | Completed | National Cancer Center, Korea | Phase 2 | 2004-02-01 | The purpose of this study is to determine whether the 2mg/kg administration of corticosteroids, in the form of methylprednisolone sodium succinate, in early phase acute respiratory distress syndrome after thoracic surgery, will reduce the postoperative mortality. |
NCT00295269 ↗ | Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1997-03-01 | The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS. |
NCT00354172 ↗ | Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. | Terminated | Masonic Cancer Center, University of Minnesota | Phase 2 | 2006-02-01 | RATIONALE: Giving chemotherapy, natural killer cells, aldesleukin, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal cells and cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, mycophenolate mofetil, and methylprednisolone before and after transplant may stop this from happening. PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation followed by donor umbilical cord blood natural killer cells, aldesleukin, and umbilical cord blood transplant works in treating patients with refractory hematologic cancer or other diseases. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METHYLPREDNISOLONE SODIUM SUCCINATE
Condition Name
Clinical Trial Locations for METHYLPREDNISOLONE SODIUM SUCCINATE
Trials by Country
Clinical Trial Progress for METHYLPREDNISOLONE SODIUM SUCCINATE
Clinical Trial Phase
Clinical Trial Sponsors for METHYLPREDNISOLONE SODIUM SUCCINATE
Sponsor Name